Literature DB >> 12063542

Quantitative and qualitative in vivo angiogenesis assay.

Marya F McCarty1, Cheryl H Baker, Corazon D Bucana, Isaiah J Fidler.   

Abstract

We describe the development and optimization of an in vivo angiogenesis assay utilizing gelfoam sponges impregnated with 0.4% agarose and different proangiogenic factors, such as basic fibroblast growth factor (bFGF), vascular epidermal growth factor (VEGF), tumor growth factor-alpha (TGF-alpha), and endothelial growth factor (EGF). The sponges are implanted into the subcutis of mice and harvested after different times. The gelfoam sponges are fixed, sectioned, and stained with fluorescent antibodies against CD31. The median number of CD31+ cells is determined in 10 different 0.159-mm2 fields. Proangiogenic molecules induced significant migration and proliferation of endothelial cells. To demonstrate the utility of this assay for evaluation of an antiangiogenic agent, mice were implanted with gelfoam sponges containing different proangiogenic factors and treated orally with water or PTK 787, a novel tyrosine kinase inhibitor with specific activity against the VEGF-R. PTK 787 significantly inhibited angiogenesis in sponges containing agarose + VEGF but not other proangiogenic molecules. The data show that the implanted gelfoam sponges provide a reliable quantitative assay to study in vivo angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063542

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesis.

Authors:  Zhi-Jian Su; Christopher N Hahn; Gregory J Goodall; Niamh M Reck; Annabell F Leske; Ann Davy; Gabriel Kremmidiotis; Mathew A Vadas; Jennifer R Gamble
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-09       Impact factor: 11.205

2.  Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine.

Authors:  Monique B Nilsson; Robert R Langley; Isaiah J Fidler
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  Noninvasive and quantitative assessment of in vivo angiogenesis using RGD-based fluorescence imaging of subcutaneous sponges.

Authors:  Michelle Keramidas; Véronique Josserand; Jean-Jacques Feige; Jean-Luc Coll
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

4.  Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

Authors:  Keila E Torres; Quan-Sheng Zhu; Katelynn Bill; Gonzalo Lopez; Markus P Ghadimi; Xianbiao Xie; Eric D Young; Juehui Liu; Theresa Nguyen; Svetlana Bolshakov; Roman Belousov; Suizhau Wang; Guy Lahat; Jun Liu; Belinda Hernandez; Alexander J Lazar; Dina Lev
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

5.  Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis.

Authors:  Taro Sakai; Krishnakumar Balasubramanian; Sourindra Maiti; Jyotsna B Halder; Alan J Schroit
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

6.  Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.

Authors:  Guy Lahat; Quan-Sheng Zhu; Kai-Lieh Huang; Suizhao Wang; Svetlana Bolshakov; Jeffery Liu; Keila Torres; Robert R Langley; Alexander J Lazar; Mien Chie Hung; Dina Lev
Journal:  PLoS One       Date:  2010-04-16       Impact factor: 3.240

7.  Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms.

Authors:  Marya F McCarty; Diane Bielenberg; Cherrie Donawho; Corazon D Bucana; Isaiah J Fidler
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

8.  Osteosarcoma cells enhance angiogenesis visualized by color-coded imaging in the in vivo Gelfoam® assay.

Authors:  Fuminari Uehara; Yasunori Tome; Shinji Miwa; Yukihiko Hiroshima; Shuya Yano; Mako Yamamoto; Sumiyuki Mii; Hiroki Maehara; Michael Bouvet; Fuminori Kanaya; Robert M Hoffman
Journal:  J Cell Biochem       Date:  2014-09       Impact factor: 4.429

9.  PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.

Authors:  K Dredge; E Hammond; P Handley; T J Gonda; M T Smith; C Vincent; R Brandt; V Ferro; I Bytheway
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

10.  A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.

Authors:  W-C Yen; R Y Prudente; M R Corpuz; A Negro-Vilar; W W Lamph
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.